Mefloquine is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of mild to moderate acute malaria (P. falciparum and P. vivax) caused by chloroquine-resistant, chloroquine-susceptible and multiple drug-resistant (including sulfadoxine and pyrimethamine-resistant) strains
- Malaria (P. falciparum and P. vivax) prophylaxis including prophylaxis of chloroquine-resistant strains of P. falciparum.
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: October 5, 2015
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Mefloquine
ID - 540338
A1 - Bartlett,John,M.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2015/10/05/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540338/all/Mefloquine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -